GRCE NASDAQ
Grace Therapeutics, Inc.
1W: -2.4%
1M: -3.3%
3M: -18.2%
YTD: -43.4%
1Y: -32.6%
$2.07
+0.03 (+1.47%)
Weekly Expected Move ±5.6%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (15)
Bank of America Corp DE Makes New Investment in Grace Therapeutics, Inc. $GRCE
Grace Therapeutics (NASDAQ:GRCE) Stock Price Down 0.9% – Time to Sell?
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
Grace Therapeutics (NASDAQ:GRCE) Trading Down 2.5% – Here’s What Happened
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
12 Health Care Stocks Moving In Tuesday's Intraday Session
Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Expands By 300.8%
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
Grace Therapeutics (GRCE) Expected to Announce Quarterly Earnings on Thursday